BSE Live
Nov 26, 16:01Prev. Close
885.10
Open Price
864.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 26, 15:59Prev. Close
885.70
Open Price
895.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
903.10 (4)
| Key Financial Ratios of Strides Pharma Science (in Rs. Cr.) | Dec 04 | |
| Per Share Ratios | ||
| Basic EPS (Rs.) | 8.64 | |
| Diluted EPS (Rs.) | 8.64 | |
| Cash EPS (Rs.) | 12.21 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 70.54 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 70.54 | |
| Dividend / Share(Rs.) | 1.50 | |
| Revenue from Operations/Share (Rs.) | 90.36 | |
| PBDIT/Share (Rs.) | 23.03 | |
| PBIT/Share (Rs.) | 19.46 | |
| PBT/Share (Rs.) | 11.74 | |
| Net Profit/Share (Rs.) | 8.64 | |
| Profitability Ratios | ||
| PBDIT Margin (%) | 25.48 | |
| PBIT Margin (%) | 21.53 | |
| PBT Margin (%) | 12.99 | |
| Net Profit Margin (%) | 9.55 | |
| Return on Networth / Equity (%) | 12.24 | |
| Return on Capital Employed (%) | 7.00 | |
| Return on Assets (%) | 5.38 | |
| Total Debt/Equity (X) | 0.89 | |
| Asset Turnover Ratio (%) | 56.35 | |
| Liquidity Ratios | ||
| Current Ratio (X) | 2.11 | |
| Quick Ratio (X) | 1.89 | |
| Inventory Turnover Ratio (X) | 11.29 | |
| Dividend Payout Ratio (NP) (%) | 17.36 | |
| Dividend Payout Ratio (CP) (%) | 12.28 | |
| Earnings Retention Ratio (%) | 82.64 | |
| Cash Earnings Retention Ratio (%) | 87.72 | |
| Valuation Ratios | ||
| Enterprise Value (Cr.) | 914.61 | |
| EV/Net Operating Revenue (X) | 3.00 | |
| EV/EBITDA (X) | 11.76 | |
| MarketCap/Net Operating Revenue (X) | 2.36 | |
| Retention Ratios (%) | 82.63 | |
| Price/BV (X) | 3.02 | |
| Price/Net Operating Revenue | 2.36 | |
| Earnings Yield | 0.04 |
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
09.09.2025
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
29.07.2025
Strides Pharma Consolidated June 2025 Net Sales at Rs 1,119.74 crore, up 2.96% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016